65,437 trials
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intra- Examiner Agreement in Angle Width by Goniometric Lens — 0.88 Kappa statistics
Chronic Hepatitis B
Primary: Percentage of Participants With HBV Recurrence Prior to or at Week 72 — 0; 0 percentage of participants
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye — 22.35; -3.98 Millimeters of Mercury (mmHg)
Primary Sclerosing Cholangitis
Primary: Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment — -117; -49; -62; -36 U/L
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Progression-free Survival — 11.0; 12.3; 15.3 months — p=0.448
Coronary Artery Disease (CAD)
Primary: Number of Participants With Reversible Defects — 84; 16; 100; 1 participants
HIV Infections · AIDS
Primary: Safety — 0; 0 participants
Superficial Femoral Artery Disease
Primary: 12-month Primary Patency Rate — 143; 72 participants — p=0.437
Myelodysplastic Syndrome
Primary: The Overall Improvement Rate — 23.3; 22.7; 16.3; 0 Percentage of Participants
Major Depressive Disorder
Primary: Change in Mean Scores on Clinical Global Impressions — -2.1 units on a scale
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 — 0.029; 0.120; 0.127; 0.138 Liters — p=<0.001
Rheumatoid Arthritis
Primary: Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-29 — 15.04 Percent change
Facial Rhytides
Primary: Inter-rater Reliability of Assessment of Facial Lines Using the 4-Point Facial Wrinkle Scale (FWS-A) — 0.653; 0.637; 0.647; 0.654 Kappa statistics
HIV Infections
Primary: Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis) — 132.30; 89.75; 49.38 nM